-
Something wrong with this record ?
Clinical correlation between disease progression and central vein sign in pediatric onset multiple sclerosis: A binational study
S. Menascu, S. Halusková, A. Pollak, P. Ryska, F. Angelucci, D. Magalashvili, D. Guber, A. Yosef, A. Kalron, M. Valis, M. Gurevich
Language English Country England, Great Britain
Document type Journal Article, Multicenter Study
- MeSH
- Child MeSH
- Humans MeSH
- Magnetic Resonance Imaging * MeSH
- Adolescent MeSH
- Brain diagnostic imaging pathology MeSH
- Cerebral Veins diagnostic imaging physiopathology MeSH
- Follow-Up Studies MeSH
- Disability Evaluation MeSH
- Disease Progression * MeSH
- Multiple Sclerosis diagnostic imaging physiopathology MeSH
- Age of Onset MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Czech Republic MeSH
- Israel MeSH
BACKGROUND: The central vein sign (CVS) has been proposed as a novel MRI biomarker to improve diagnosis of pediatric-onset MS (POMS). However, the role of CVS in POMS progression has yet to be discovered. OBJECTIVES: To investigate the appearance of CVS and its correlation with POMS disease progression. METHODS: One hundred fifty-six POMS from two MS centers in Israel and Czech Republic MS centers were followed for five years. Patient assessment was performed by the Expanded Disability Status Scale (EDSS) and Annual Relapse Rate (ARR). Patients in whom at least 40 % of brain MRI lesions had CVS ("rule of 40") were determined as CVS-positive. RESULTS: The total group of POMS consisted of 96 CVS-negative (61.5 %), aged 14.6 ± 1.9 years, EDSS 2.0, 75 % Interquartile Range (IQR) 1.0-3.0, disease duration (DD) 6.28 ± 0.38 years, and 60 CVS-positive (38.5 %), aged 15.1 ± 0.3 years, EDSS 2.0, IQR 1.5-3.0, DD 5.62 ± 0.13 years, were analyzed. After a three and five-year follow-up, the CVS-positive patients had higher EDSS scores than those who were CVS-negative, 2.0, IQR 1.0-2.5, vs 1.0, IQR 1.0-2.0, (p = 0.009) and 2.0, IQR 1.0-3.25 vs 1.0, IQR 1.0-2.0, (p = 0.0003), respectively. Patients with CVS-positive POMS were characterized by a significantly higher ARR (0.78 ± 0.08 vs 0.57 ± 0.04, p = 0.002). These results were confirmed in subgroups of Disease Modifying Treatments (DMT) untreated and treated patients. CONCLUSION: CVS-positive POMS is characterized by higher disability progression than CVS-negative, indicating the importance of CVS in disease pathogenesis.
Department of Radiology University Hospital Hradec Králové Hradec Králové Czech Republic
Faculty of Medical and Health Sciences Tel Aviv University Israel
Multiple Sclerosis Center Sheba Medical Center Ramat Gan Israel
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014050
- 003
- CZ-PrNML
- 005
- 20240905134046.0
- 007
- ta
- 008
- 240725e20240424enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpn.2024.04.007 $2 doi
- 035 __
- $a (PubMed)38705014
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Menascu, Shay $u Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Electronic address: Shay.Menascu@sheba.health.gov.il
- 245 10
- $a Clinical correlation between disease progression and central vein sign in pediatric onset multiple sclerosis: A binational study / $c S. Menascu, S. Halusková, A. Pollak, P. Ryska, F. Angelucci, D. Magalashvili, D. Guber, A. Yosef, A. Kalron, M. Valis, M. Gurevich
- 520 9_
- $a BACKGROUND: The central vein sign (CVS) has been proposed as a novel MRI biomarker to improve diagnosis of pediatric-onset MS (POMS). However, the role of CVS in POMS progression has yet to be discovered. OBJECTIVES: To investigate the appearance of CVS and its correlation with POMS disease progression. METHODS: One hundred fifty-six POMS from two MS centers in Israel and Czech Republic MS centers were followed for five years. Patient assessment was performed by the Expanded Disability Status Scale (EDSS) and Annual Relapse Rate (ARR). Patients in whom at least 40 % of brain MRI lesions had CVS ("rule of 40") were determined as CVS-positive. RESULTS: The total group of POMS consisted of 96 CVS-negative (61.5 %), aged 14.6 ± 1.9 years, EDSS 2.0, 75 % Interquartile Range (IQR) 1.0-3.0, disease duration (DD) 6.28 ± 0.38 years, and 60 CVS-positive (38.5 %), aged 15.1 ± 0.3 years, EDSS 2.0, IQR 1.5-3.0, DD 5.62 ± 0.13 years, were analyzed. After a three and five-year follow-up, the CVS-positive patients had higher EDSS scores than those who were CVS-negative, 2.0, IQR 1.0-2.5, vs 1.0, IQR 1.0-2.0, (p = 0.009) and 2.0, IQR 1.0-3.25 vs 1.0, IQR 1.0-2.0, (p = 0.0003), respectively. Patients with CVS-positive POMS were characterized by a significantly higher ARR (0.78 ± 0.08 vs 0.57 ± 0.04, p = 0.002). These results were confirmed in subgroups of Disease Modifying Treatments (DMT) untreated and treated patients. CONCLUSION: CVS-positive POMS is characterized by higher disability progression than CVS-negative, indicating the importance of CVS in disease pathogenesis.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a roztroušená skleróza $x diagnostické zobrazování $x patofyziologie $7 D009103
- 650 _2
- $a mozkové žíly $x diagnostické zobrazování $x patofyziologie $7 D002550
- 650 _2
- $a mozek $x diagnostické zobrazování $x patologie $7 D001921
- 650 _2
- $a posuzování pracovní neschopnosti $7 D004185
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a věk při počátku nemoci $7 D017668
- 651 _2
- $a Izrael $7 D007557
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Halusková, Simona $u Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic. Department of Neurology, Faculty of Health Studies, Pardubice University and Pardubice Hospital, Pardubice, Czech Republic. Electronic address: sim.haluskova@gmail.com
- 700 1_
- $a Pollak, Amir $u Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Electronic address: Amir.Pollak@sheba.health.gov.il
- 700 1_
- $a Ryska, Pavel $u Department of Radiology, University Hospital Hradec Králové, Hradec Králové, Czech Republic. Electronic address: pavel.ryska@fnhk.cz
- 700 1_
- $a Angelucci, Francesco $u Department of Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic and International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Electronic address: fangelucci@hotmail.com
- 700 1_
- $a Magalashvili, David $u Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Electronic address: David.Magalashvili@sheba.health.gov.il
- 700 1_
- $a Guber, Diana $u Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Electronic address: Diana.Guber@sheba.health.gov.il
- 700 1_
- $a Yosef, Arthur $u Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel. Electronic address: artyosef@gmail.com
- 700 1_
- $a Kalron, Alon $u Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Electronic address: Alon.Kalron@sheba.health.gov.il
- 700 1_
- $a Valis, Martin $u Research Institute for Biomedical Science, Hradec Králové, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Electronic address: valismar@seznam.cz
- 700 1_
- $a Gurevich, Michael $u Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Electronic address: Michael.Gurevich@sheba.health.gov.il
- 773 0_
- $w MED00149836 $t European journal of paediatric neurology $x 1532-2130 $g Roč. 50 (20240424), s. 81-85
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38705014 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134040 $b ABA008
- 999 __
- $a ok $b bmc $g 2143683 $s 1225916
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 50 $c - $d 81-85 $e 20240424 $i 1532-2130 $m European journal of paediatric neurology $n Eur J Paediatr Neurol $x MED00149836
- LZP __
- $a Pubmed-20240725
